Recruiting studies: Cd30 Peripheral T Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT06176690 CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Phase 2 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT04083495 Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07074457 Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT04288726 Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spa
Phase N/A · 37 location(s) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ó · NCT07624838 Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Phase 2 · 2 location(s) · Yale University · NCT05313243

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.